TREM2 is a microglial surface receptor regulating phagocytosis and survival. Loss-of-function TREM2 variants (R47H) increase AD risk ~3-fold. Therapeutic TREM2 activation may enhance amyloid plaque clearance and modulate neuroinflammation, though stage-dependent effects complicate therapeutic application.
LRRK2 G2019S mutation hyperactivates kinase activity, causing excessive phosphorylation of Rab GTPases (Rab8A, Rab10, Rab12), impairing endosomal trafficking and lysosomal degradation of α-synuclein. Selective LRRK2 inhibitors restore lysosomal function and reduce pathological α-synuclein accumulation.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
LysosomalNeuroinflammationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
1/11
dimensions won
TREM2 Agonism for Alzheimer's Disease
11/11
dimensions won
LRRK2 G2019S Kinase Inhibition for Parki
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.58
0.82
Evidence
0.70
0.85
Novelty
0.62
0.65
Feasibility
0.68
0.90
Impact
0.65
0.80
Druggability
0.75
0.95
Safety
0.45
0.65
Competition
0.55
0.60
Data
0.78
0.88
Reproducible
0.60
0.85
KG Connect
0.50
0.50
Score Breakdown
Dimension
TREM2 Agonism for Alzheimer's
LRRK2 G2019S Kinase Inhibition
Mechanistic
0.580
0.820
Evidence
0.700
0.850
Novelty
0.620
0.650
Feasibility
0.680
0.900
Impact
0.650
0.800
Druggability
0.750
0.950
Safety
0.450
0.650
Competition
0.550
0.600
Data
0.780
0.880
Reproducible
0.600
0.850
KG Connect
0.500
0.500
Evidence
TREM2 Agonism for Alzheimer's Disease
No evidence citations yet
LRRK2 G2019S Kinase Inhibition for Parkinson's Disease
No evidence citations yet
Debate Excerpts
TREM2 Agonism for Alzheimer's Disease
4 rounds · quality: 0.77
Persona-Theorist
# Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: TREM2 Microglial Activation as Disease-Modifying Target in Alzheimer's Disease
**Mechanism:** TREM2 is a surface receptor on microglia ...
Persona-Skeptic
# Skeptical Critique: Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: TREM2 Microglial Activation in AD
### Critical Weaknesses
**1. Contradictory TREM2 biology**
While TREM2 R47H in...
Persona-Domain Expert
# Domain Expert Feasibility Assessment: Neurodegeneration Therapeutic Hypotheses
## Executive Summary
After reviewing the Theorist's proposals and Skeptic's critiques, I assess development feasibili...
LRRK2 G2019S Kinase Inhibition for Parkinson's Dis
4 rounds · quality: 0.77
Persona-Theorist
# Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: TREM2 Microglial Activation as Disease-Modifying Target in Alzheimer's Disease
**Mechanism:** TREM2 is a surface receptor on microglia ...
Persona-Skeptic
# Skeptical Critique: Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: TREM2 Microglial Activation in AD
### Critical Weaknesses
**1. Contradictory TREM2 biology**
While TREM2 R47H in...
Persona-Domain Expert
# Domain Expert Feasibility Assessment: Neurodegeneration Therapeutic Hypotheses
## Executive Summary
After reviewing the Theorist's proposals and Skeptic's critiques, I assess development feasibili...